While many people are familiar with common forms of hair loss like male or female pattern baldness, some individuals experience more severe and widespread conditions. Among these are alopecia totalis and alopecia universalis, two distinct but related autoimmune disorders that result in significant hair loss. These conditions go beyond typical thinning, leading to the complete absence of hair in specific areas or even across the entire body. Understanding
the unique characteristics, suspected causes, and evolving treatment approaches for these severe forms of alopecia is crucial for those affected and the medical community.
Alopecia Totalis: Complete Scalp and Facial Hair Loss
Alopecia totalis is characterized by the complete loss of all hair on the head and face. This means not only the hair on the scalp but also eyebrows and eyelashes are affected. The exact causes of alopecia totalis are not entirely clear, but it is widely believed to be an autoimmune disorder. In autoimmune conditions, the body's immune system mistakenly attacks its own healthy cells, in this case, the hair follicles.
Research suggests there may be a genetic link to alopecia totalis. Specifically, the presence of certain human leukocyte antigens (HLA), namely DRB1*0401 and DQB1*0301, has been found to be associated with long-standing alopecia totalis. This indicates that some individuals may have a genetic predisposition that makes them more susceptible to developing this severe form of hair loss. While the condition can be distressing due to its visible nature, individuals with alopecia totalis are generally healthy otherwise.
Alopecia Universalis: The Most Severe Form
Alopecia universalis (AU), also known as alopecia areata universalis, represents the most severe manifestation of alopecia areata. This condition involves the loss of all body hair, extending beyond the head and face to include eyebrows, eyelashes, chest hair, armpit hair, and pubic hair. Despite the extensive hair loss, people with alopecia universalis are typically healthy, experience no other symptoms, and have a normal life expectancy.
Like alopecia totalis, alopecia universalis is currently understood to be an an autoimmune disorder. In this scenario, a person's immune system attacks hair follicles throughout the entire body. Genetic factors are also believed to contribute to AU, with approximately 20% of affected individuals having a family member who also experiences some form of alopecia. This familial pattern further supports the role of genetic predisposition in the development of the condition.
Evolving Treatment Approaches for Severe Alopecia
Many treatments have been explored for alopecia universalis and alopecia totalis, though there is no single accepted therapy that has systematically proven effective with benefits outweighing costs and side effects. Immunomodulatory agents, such as imiquimod, have been investigated. Tofacitinib citrate is another agent that has shown potential benefits. For example, in June 2014, a 25-year-old man with almost no body hair was reported to have regrown a full head of hair, along with eyebrows, eyelashes, and other body hair, after eight months of tofacitinib treatment. However, treatments like tofacitinib can be expensive and have side effects, and their effects often disappear if treatment is discontinued.
Contact immunotherapy is another approach, involving the use of contact allergens like diphencyprone and squaric acid dibutylester. The goal is to induce an immune response that is thought to counteract the action of cells causing hair loss. A review combining 45 studies with 2,227 patients showed some hair regrowth in 54.5% and complete hair regrowth in 24.9% of patients with alopecia totalis and universalis using this method. However, contact immunotherapy can also have serious side effects, such as severe dermatitis. Topical and intralesional corticosteroids, including clobetasol propionate, have also demonstrated effectiveness. A controlled study of 28 patients found positive terminal hair growth in 28.5% using a 0.05% clobetasol propionate ointment. Intralesional applications of steroids are generally considered more effective than topical ones, though the main side effect is an increased risk of cutaneous atrophy at the treatment site, with folliculitis being an occasional complication.
Recent research has focused on Janus kinase (JAK) inhibitors, previously used for cancer and arthritis. These inhibitors have shown promising results in initial trials for alopecia patients. Multiple successful cases have been reported, including a 22-year-old man with a history of AU and atopic dermatitis who experienced hair regrowth on all affected body parts and improved atopic dermatitis after ten months of treatment with a JAK inhibitor. Current findings suggest that systemic JAK inhibitors may prevent and eliminate the development of alopecia areata, while topical JAK inhibitors promote hair regrowth and reverse established disease. Many clinical trials are ongoing for JAK inhibitors like ruxolitinib and tofacitinib, offering hope for future treatments.
